1. 17 years in markets, tracked cannabis’s long haul from fringe to fundable. Skeptical of hype, bullish on CBD’s slow rebound. 2. Covered biotech for 12 years, pivoted to cannabis in 2017. I’m the ‘show me the data’ type, not the ‘next big thing’ guy